COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study

Abstract

More than 2 years after the pandemic, the availability of vaccination and the use of monoclonal antibodies and direct antivirals have changed the fate of COVID-19, allowing for a better management of the disease, reducing hospitalization rates, and improving survival. This study aims to describe the outcome of COVID-19 in a cohort of solid organ transplant recipients and the impact of novel antivirals against SARS-CoV-2. We conducted an observational retrospective cohort study. We enrolled solid organ transplant recipients with COVID-19 attending the A.O.U. Federico II of Naples and followed up from January 2022 to July 2022. We enrolled 40 SOTs with COVID-19. Our experience highlights the favorable impact of therapies with antivirals and monoclonal antibodies in the early stages of COVID-19. Interesting data concern the impact of immunosuppressive therapy on COVID-19, in particular the role of Mycophenolate (associated with deterioration to severe COVID-19) and Everolimus (protective for progression to severe disease) needs to be investigated. Our experience also confirms the fundamental role of vaccination and in particular the importance of the booster dose.